The End of the Surgical Cycle? Krystal Biotech's Bold Pivot in Gorlin Syndrome

PITTSBURGH, PA – October 15, 2026 – For patients living with Gorlin syndrome, the passage of time is often measured not in years, but in surgeries. The rare genetic condition, which affects an estimated 10,000 individuals in the United States, is characterized by the relentless, lifelong emergence of basal cell carcinomas (BCCs). From as early as infancy, patients can develop hundreds of these skin cancers, necessitating repetitive, disfiguring surgical excisions that leave profound physical and psychological scars.

Today, however, a fundamental shift in how we treat this exhausting condition may be on the horizon. Krystal Biotech has unveiled compelling proof-of-concept clinical data for KB113, a novel intratumoral immunotherapy. While the data stems from a small pilot study of just three patients, the results are striking enough to warrant immediate attention from both the oncology community and rare disease advocates.

In the trial, over 80 percent of assessed basal cell carcinoma lesions regressed across the three subjects treated with KB113. But the true breakthrough lies not just in the tumors that were directly injected, but in those that were left entirely untouched.

The Abscopal Horizon: Engineering Systemic Immunity

To understand why this data is generating such intense interest, one must look closely at the mechanism of action behind KB113. The therapy leverages an engineered, replication-defective herpes simplex virus type 1 (HSV-1) vector—a platform similar to the one Krystal Biotech successfully utilized for its approved epidermolysis bullosa treatment, VYJUVEK.

In the case of KB113, the viral vector is designed to deliver localized expression of two potent cytokines: interleukin-2 (IL-2) and interleukin-12 (IL-12). When injected directly into a tumor, these cytokines act as a localized spark, transforming the tumor microenvironment from immunosuppressive to immunostimulatory. IL-12 directs adaptive immunity towards a Th1 response, promoting the activation of natural killer cells and enhancing interferon-gamma production. This effectively turns a "cold" tumor microenvironment "hot." IL-2 then steps in to ensure the proliferation of these newly activated effector T cells.

Once the local tumor is destroyed, tumor-associated antigens are released. Antigen-presenting cells pick these up, travel to the draining lymph nodes, and prime a systemic T-cell response. These systemic T-cells then patrol the body, hunting down the non-injected tumors.

The clinical results from the Gorlin Syndrome Pilot Study suggest this abscopal effect is actively occurring. Across the 14-week treatment period, 85.1 percent of non-injected lesions showed clinical regression, with over 57 percent regressing by more than half.

"The breadth and depth of responses reported today on landmark lesions located in various parts of the patient’s body showcase the systemic immune-activating potential of HSV-1 encoded IL-2 and IL-12 and have exciting implications for Krystal and the many patients we aim to serve," said Suma Krishnan, President of Research and Development at Krystal Biotech.

Furthermore, histological analysis of one injected lesion from each patient that had achieved at least 90 percent clinical regression confirmed complete clearance, with no evidence of residual tumor tissue remaining.

A Stark Contrast to the Current Standard of Care

The significance of KB113’s efficacy is magnified when juxtaposed with the current standard of care for advanced BCCs. Today, systemic therapy primarily relies on Hedgehog pathway inhibitors (HHIs) such as vismodegib and sonidegib. The Hedgehog signaling pathway is aberrantly activated in almost all BCCs, and these oral medications target the Smoothened (SMO) receptor to block this pathway.

While scientifically elegant and highly effective at shrinking tumors, the systemic blockade of this pathway disrupts normal tissue maintenance, leading to a severe, often intolerable toxicity profile. Patients on HHIs frequently suffer from debilitating muscle spasms, profound hair loss, severe weight loss, and dysgeusia—a complete loss or alteration of taste.

The clinical reality of these drugs is grim. Studies indicate that up to 86 percent of patients in real-world settings permanently discontinue sonidegib, largely due to adverse events. In pivotal trials for vismodegib, over half of patients discontinued treatment for similar reasons. For a chronic condition like Gorlin syndrome, where lifelong management is required, a treatment that patients cannot tolerate is fundamentally flawed.

By contrast, KB113 was remarkably well tolerated. In the pilot study, all reported adverse events were mild to moderate in severity, transient, and resolved completely during the study period. The ability to generate systemic anti-tumor immunity without the systemic toxicity of oral inhibitors is a massive leap forward.

"For individuals living with Gorlin syndrome, the lifelong emergence of multiple BCCs creates an immense cumulative treatment burden—often resulting in extensive scarring and significant impacts on quality of life," noted Dr. Shireen V. Guide, the study investigator from Mission Dermatology Center. "The observed antitumor responses with KB113 across both injected and non-injected lesions represent encouraging preliminary findings that strongly support its continued clinical development."

Navigating the Regulatory Reality of an N-of-3 Cohort

Despite the undeniable promise of the data, the reality remains that this trial involved only three patients. In the realm of clinical development, an N-of-3 cohort is a signal, not a definitive conclusion. The challenge now falls to Krystal Biotech to design a registrational trial that satisfies regulatory requirements while navigating the inherent difficulties of studying a rare disease.

The United States Food and Drug Administration (FDA) has historically recognized the unique hurdles of rare disease drug development. With the recent announcement of the FDA’s Rare Disease Framework Initiative in October 2026, the agency has signaled a continued willingness to adopt "fit-for-purpose" evidentiary standards. This means that while massive, placebo-controlled Phase 3 trials may be mathematically impossible for a disease with only 10,000 domestic patients, robust single-arm studies utilizing objective endpoints—such as histological clearance and reduction in new lesion formation—can serve as viable pathways to approval.

Krystal Biotech is uniquely positioned to navigate this landscape. The company has already successfully guided a gene therapy for a rare dermatological condition through the FDA with VYJUVEK. They have initiated discussions with the agency regarding the advanced clinical development of KB113, and the industry will be watching closely to see what trial design the FDA mandates.

Beyond Monogenic Skin Diseases

From an analytical perspective, the KB113 data represents more than just a potential new therapy for Gorlin syndrome; it marks a strategic pivot for Krystal Biotech. By taking a platform originally designed for monogenic skin diseases and modifying it to tackle oncology, the company is proving the versatility of its engineered HSV-1 vector.

If the localized delivery of IL-2 and IL-12 can reliably induce an abscopal effect in BCCs, it opens the door to investigating this approach in other localized solid tumors that have traditionally resisted immunotherapy. Krystal's broader oncology program, which includes the higher-dose KB707 for solid tumors, will undoubtedly benefit from the immunological validation provided by this Gorlin syndrome pilot.

For now, however, the focus remains firmly on the tangible difference this could make for Gorlin syndrome patients. If subsequent trials mirror the success of this pilot study, we may be witnessing the end of the surgical cycle. A future where patients can manage their condition with periodic, localized injections rather than a lifetime of scalpels and scarring is no longer just a theoretical hope—it is a clinical possibility actively taking shape.